Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Director | June 03, 2026 | June 05, 2026 |
| PERNIX THERAPEUTICS HOLDINGS, INC.PTX · Entity 161208 | Director | May 22, 2018 | May 23, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 101,109 |
Reported balance
After 2026-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 11,610 · Balance 101,109 F1: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.15 · Expires 2036-06-03 | Direct | 16,999 |
Reported balance
After 2026-06-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-03 · Grant · Acquired 16,999 · Balance 16,999 F2: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
F2: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
PERNIX THERAPEUTICS HOLDINGS, INC.
Report date May 22, 2018 · Filed May 23, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.63 · Expires 2028-05-21 | Direct | 25,000 |
Reported balance
After 2018-05-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-22 · Grant · Acquired 25,000 · Balance 25,000 F1: The stock option vests in four equal annual installments of 6,250 shares over a four-year period, with the first installment vesting on May 22, 2019, which is the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in four equal annual installments of 6,250 shares over a four-year period, with the first installment vesting on May 22, 2019, which is the one-year anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2018 Filed May 17, 2018 20:18 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 40,000 | $3.44 | $137,600.00 |
DisclosureSEC source: 0001209191-18-030889 · doc4.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 14:49 UTC | PERNIX THERAPEUTICS HOLDINGS, INC. PTX · Entity 161208 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.97 | $0.00 |
DisclosureSEC source: 0001136261-17-000285 · primary_doc.xml · derivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-11-14 F1 · derivative.exercise_date: The stock option vests in four equal annual installments of 12,500 shares over a four-year period, with the first installment vesting on November 15, 2018, which is the one-year anniversary of the grant date. Read SEC document |
| November 21, 2016 Filed Nov 22, 2016 16:15 UTC | PERNIX THERAPEUTICS HOLDINGS, INC. PTX · Entity 161208 | GrantStock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001136261-16-000687 · primary_doc.xml · derivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2026-11-20 F1 · derivative.exercise_date: The stock option vests in annual installments of approximately 1,000 shares, commencing on the first anniversary of November 21, 2016, with the final installment vesting on the fourth anniversary of the vesting start date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.